Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC’s First Committee Recommends Approval for Takeda’s Lotriga
August 7, 2012
- Health Minister Komiyama Continues Requesting IPV Price Cut
August 6, 2012
- DTP-IPV to Be Introduced in November; MHLW Anticipates Supply of 1.47 Million Doses by End of FY2012
August 6, 2012
- Ratio of Generics Rises 0.3 Points to 23.8%: Survey
August 3, 2012
- PMDA Determines Role of Science Board to Enhance Review System
August 2, 2012
- Council Generally Approves Revised Basic Policy for 2nd Med. Expenditure Optimization Plan; Regional Targets for Use of Generics to Be Included
August 2, 2012
- MHLW Investigative Commission Compiles Report to Improve Distribution of Novel Influenza Vaccines
August 1, 2012
- Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
- MHLW to Issue Development Requests for 8 Drugs/Indications Determined to Have Unmet Medical Needs by Council on Unapproved Drugs
August 1, 2012
- MHLW Withdraws Development Request for Decitabine in Response to Approval for New Drug with Same Indication
August 1, 2012
- MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
- MHLW Approves Class 1 OTC Drugs for Allergic Rhinitis
July 30, 2012
- MHLW Reports Revisions of Package Insert for Telavic
July 27, 2012
- PAFSC’s 2nd Committee Recommends Approval of 2 DPT-IPV Vaccines; Introduction Expected in November
July 26, 2012
- PAFSC’s 2nd Committee Recommends Orphan Drug Designation for 3 Products Including Thyroid Cancer Treatment
July 26, 2012
- MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
- MHLW Approves Revision to Kitasato Daiichi Sankyo Vaccine’s Management Resource Reuse Plan
July 25, 2012
- PAFSC’s First Committee to Review 4 Products Including Lotriga from Takeda on August 3
July 24, 2012
- PAFSC’s Second Committee Recommends Approval for Symbicort for COPD
July 24, 2012
- NIBIO to Play Important Role in Collaboration between Industry, Government, Academia: Director General Yamanishi
July 24, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…